Synthetic hexapeptide secretagogue
Also indexed as: Examorelin
A small human physiology study demonstrates hormone responses, not long-term clinical or athletic benefit.
Unfamiliar word? Open this panel for simple explanations, right here.
10 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Hexarelin is a synthetic hexapeptide in the growth hormone secretagogue family. It has been investigated in endocrine physiology rather than established as a general recovery therapy.
Ghrelin / GH–IGF-1
Activates the growth hormone secretagogue/ghrelin receptor system. Human studies compare GH and other endocrine responses with GHRH and ghrelin.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryHuman evidence is still developing
Studies in people exist, but the findings may be small, narrow, mixed or still need confirmation. A hormone or cell marker is not necessarily a health benefit.
For this research: A small human physiology study demonstrates hormone responses, not long-term clinical or athletic benefit.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
The cited human study compares endocrine responses to ghrelin, hexarelin and GHRH.
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Pituitary endocrine responses compared with ghrelin and GHRH.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalGH, cortisol and prolactin responses may differ by context. Glucose effects, fluid retention and long-term endocrine risks require clinical study.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone
Journal of Clinical Endocrinology & Metabolism
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Beyond the library
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Continue to our existing activation & intake page.
Education, not a prescription. Research summaries are not medical advice, dosing instructions, or an offer to sell. Mechanistic findings do not establish clinical effectiveness. US regulatory status is product- and indication-specific and may change. Discuss health decisions with a licensed clinician.
